Cetera Investment Advisers’s Ocular Therapeutix OCUL Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.48M	Buy	764,615 +42,075	+6%	+$401K	0.01%	1333
2025 Q4	$8.77M	Buy	722,540 +8,474	+1%	+$103K	0.01%	1109
2025 Q3	$8.35M	Buy	714,066 +8,660	+1%	+$104K	0.01%	1103
2025 Q2	$6.55M	Sell	705,406 -15,958	-2%	-$125K	0.01%	1033
2025 Q1	$5.29M	Sell	721,364 -2,476	-0.3%	-$19K	0.01%	1073
2024 Q4	$6.18M	Buy	723,840 +4,342	+0.6%	+$42.4K	0.01%	935
2024 Q3	$6.26M	Sell	719,498 -19,546	-3%	-$161K	0.01%	899
2024 Q2	$5.06M	Buy	739,044 +13,054	+2%	+$80.6K	0.01%	991
2024 Q1	$6.61M	Buy	725,990 +49,590	+7%	+$352K	0.02%	838
2023 Q4	$3.02M	Buy	676,400 +66,300	+11%	+$196K	0.02%	620
2023 Q3	$1.92M	Sell	610,100 -1,150	-0.2%	-$4.71K	0.02%	771
2023 Q2	$3.15M	Buy	611,250 +10,100	+2%	+$60.1K	0.03%	585
2023 Q1	$3.17M	Buy	601,150 +5,950	+1%	+$28.3K	0.03%	547
2022 Q4	$1.67M	Sell	595,200 -9,350	-2%	-$31K	0.02%	773
2022 Q3	$2.51M	Buy	604,550 +5,400	+0.9%	+$27.2K	0.05%	388
2022 Q2	$2.41M	Buy	599,150 +32,400	+6%	+$122K	0.04%	465
2022 Q1	$2.81M	Buy	566,750 +59,000	+12%	+$327K	0.04%	449
2021 Q4	$3.54M	Buy	507,750 +75,650	+18%	+$587K	0.05%	381
2021 Q3	$4.32M	Buy	+432,100	New	+$4.85M	0.07%	293